Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
Type:
Grant
Filed:
February 2, 2006
Date of Patent:
March 31, 2020
Assignees:
The General Hospital Corporation, Wyeth LLC
Inventors:
Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.
Type:
Grant
Filed:
July 11, 2016
Date of Patent:
March 24, 2020
Assignees:
Wyeth LLC, The General Hospital Corporation
Inventors:
Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
Type:
Grant
Filed:
March 20, 2019
Date of Patent:
March 24, 2020
Assignee:
Wyeth LLC
Inventors:
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Maninder K. Sidhu, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint
Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Type:
Grant
Filed:
June 5, 2017
Date of Patent:
March 17, 2020
Assignee:
Wyeth LLC
Inventors:
Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
Abstract: The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
December 24, 2019
Assignee:
Wyeth LLC
Inventors:
Annaliesa Sybil Anderson, Kathrin Ute Jansen, Mark Edward Ruppen, Justin Keith Moran, Susan Kay Hoiseth
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Type:
Grant
Filed:
June 24, 2019
Date of Patent:
December 17, 2019
Assignee:
Wyeth, LLC
Inventors:
Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
Type:
Grant
Filed:
August 8, 2018
Date of Patent:
November 5, 2019
Assignee:
Wyeth, LLC
Inventors:
Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Type:
Application
Filed:
June 24, 2019
Publication date:
October 17, 2019
Applicant:
Wyeth, LLC
Inventors:
Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naive adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
Type:
Grant
Filed:
May 18, 2017
Date of Patent:
September 10, 2019
Assignee:
Wyeth LLC
Inventors:
George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Type:
Grant
Filed:
December 13, 2018
Date of Patent:
August 13, 2019
Assignee:
Wyeth, LLC
Inventors:
Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
Type:
Grant
Filed:
November 22, 2017
Date of Patent:
August 6, 2019
Assignee:
Wyeth, LLC.
Inventors:
John Wozney, Howard Seeherman, Christopher Todd Brown
Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
Type:
Grant
Filed:
May 19, 2016
Date of Patent:
July 23, 2019
Assignee:
Wyeth, LLC
Inventors:
Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya Bazhina
Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
Type:
Application
Filed:
March 12, 2019
Publication date:
July 11, 2019
Applicant:
Wyeth LLC
Inventors:
Amanda R. Alley, William A. Bubnis, Stephanie Shield
Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Type:
Grant
Filed:
December 13, 2018
Date of Patent:
June 4, 2019
Assignee:
Wyeth, LLC
Inventors:
Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
Type:
Grant
Filed:
May 31, 2017
Date of Patent:
June 4, 2019
Assignee:
Wyeth LLC
Inventors:
David Hugh Giamalva, Gary Bruce Anderson
Abstract: Methods for producing proteins, for example, recombinant meningococcal 2086 proteins, using fed-batch fermentation with continuous input of an inducer after achieving a threshold parameter, and continuous input of a carbon source, for example, a constant rate input, to improve protein yields, as well as high density protein compositions for use in the methods of the present invention, are provided.
Type:
Grant
Filed:
February 1, 2016
Date of Patent:
May 28, 2019
Assignee:
Wyeth, LLC
Inventors:
Wei-Qiang Willie Sun, Earl Joseph Pursell
Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
Type:
Grant
Filed:
March 5, 2018
Date of Patent:
May 21, 2019
Assignee:
Wyeth LLC
Inventors:
Eric J. Benjamin, Wendy A. Dulin, Yanning Lin, Kai Zhuang
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Type:
Application
Filed:
December 13, 2018
Publication date:
April 25, 2019
Applicant:
Wyeth, LLC
Inventors:
Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Type:
Application
Filed:
December 13, 2018
Publication date:
April 25, 2019
Applicant:
Wyeth, LLC
Inventors:
Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen